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There is still a lively debate about whether mesenchymal stem cells (MSCs) promote or suppress antitumor immune response.
Although several possible explanations have been proposed, including different numbers of injected and engrafted MSCs,
heterogeneity in phenotype, and function of tumor cells, the exact molecular mechanisms responsible for opposite effects of
MSCs in modulation of antitumor immunity are still unknown. Herewith, we used a B16F10 murine melanoma model to
investigate whether timing of MSC administration in tumor-bearing mice was crucially important for their effects on antitumor
immunity. MSCs, intravenously injected 24 h after melanoma induction (B16F10+MSC1d-treated mice), significantly enhanced
natural killer (NK) and T cell-driven antitumor immunity, suppressed tumor growth, and improved survival of melanoma-
bearing animals. Significantly higher plasma levels of antitumorigenic cytokines (TNF-α and IFN-γ), remarkably lower plasma
levels of immunosuppressive cytokines (TGF-β and IL-10), and a significantly higher number of tumor-infiltrating, IFN-γ-
producing, FasL- and granzyme B-expressing NK cells, IL-17-producing CD4+Th17 cells, IFN-γ- and TNF-α-producing CD4
+Th1 cells, and CD8+cytotoxic T lymphocytes (CTLs) were observed in B16F10+MSC1d-treated mice. On the contrary, MSCs,
injected 14 days after melanoma induction (B16F10+MSC14d-treated mice), promoted tumor growth by suppressing antigen-
presenting properties of tumor-infiltrating dendritic cells (DCs) and macrophages and by reducing tumoricidal capacity of NK
cells and T lymphocytes. Significantly higher plasma levels of TGF-β and IL-10, remarkably lower plasma levels of TNF-α and
IFN-γ, and significantly reduced number of tumor-infiltrating, I-A-expressing, and IL-12-producing macrophages, CD80- and
I-A-expressing DCs, granzyme B-expressing CTLs and NK cells, IFN-γ- and IL-17-producing CTLs, CD4+Th1, and Th17 cells
were observed in B16F10+MSC14d-treated animals. In summing up, the timing of MSC administration into the tumor
microenvironment was crucially important for MSC-dependent modulation of antimelanoma immunity. MSCs transplanted
during the initial phase of melanoma growth exerted tumor-suppressive effect, while MSCs injected during the progressive stage
of melanoma development suppressed antitumor immunity and enhanced tumor expansion.
1. Introduction
Melanoma is nowadays considered as one of the most aggres-
sive and the fastest growing malignant tumors worldwide [1].
Although a primary cutaneous melanoma can be managed
by surgery, the advanced metastatic melanoma requires use
of modern molecular mechanism-based therapeutic
approaches [1]. The immuno- and targeted drug therapies,
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which interfere with oncoprotein and immune checkpoint
pathways, were able to positively impact survival of patients
with advanced melanoma [2]. Unfortunately, the success rate
is being hampered by a number of factors including drug
resistance, heterogeneous phenotype of melanoma cells,
and impaired activation of antitumor immune response [2].
Therefore, new and more effective strategies are needed for
patients who did not receive optimal benefit from currently
used therapeutic approaches.
Mesenchymal stem cells (MSCs) are nonhematopoietic,
multipotent stem cells that reside in almost all postnatal tis-
sues [3]. As cells of mesodermal origin, MSCs are considered
as an integral part of the tumor stromal microenvironment,
where, together with malignant cells, fibroblasts, pericytes,
and endothelial cells, it produces trophic and growth factors
and immuno- and angiomodulatory molecules and regulates
tumor development [4]. Additionally, MSCs express a large
number of chemokine receptors and exhibit strong tropism
towards cancer cells [5]. After systemic administration, MSCs
engraft in the tumormicroenvironment where, in a juxtacrine
and paracrine manner, it regulates expansion of malignant
cells and modulates antitumor immunity [6]. Due to their
tumor-homing capacity, MSCs were used as a vehicle to
deliver cytotoxic drugs, proinflammatory cytokines, and cell
cycle-interfering microRNAs in the tumors, attenuating their
growth and progression [7]. MSCs modulate phenotype and
function of all immune cells that play an important role in
antitumor immune response [8]. MSCs regulate antigen-
presenting properties of macrophages and dendritic cells
(DCs), cytotoxicity of natural killer (NK) and CD8+T cells
(CTLs), and cytokine production in CD4+T helper cells [8].
Accordingly, effects ofMSC-dependentmodulation of antitu-
mor immunity have been explored in a large number of exper-
imental studies, but surprisingly, opposite results were
reported. While several research groups demonstrated that
MSCs suppressed antitumor immune response and enhanced
tumor progression [9–11], experimental findings presented
by other researchers indicated that MSC-based therapy
favored development of strong antitumor immunity that
inhibited expansion of malignant cells [9–13]. Although
several possible explanations for these contradictory findings
have been proposed, including different numbers of injected
and engrafted MSCs, diverse route of their administration,
heterogeneity in phenotype, and function of tumor cells [12,
13], the exact molecular mechanisms responsible for opposite
effects of MSCs in modulation of tumor growth are still
unknown. Recently, Zong and colleagues indicated that
MSC-based effects on progression and metastasis of hepa-
tocellular carcinoma (HCC) depended on the time of MSC
administration in the tumor-bearing animals [14]. Injec-
tion of MSCs in the initial phase of HCC development
resulted in tumor suppression, while MSCs administered
in the progressive stage of tumor growth promoted pro-
gression and metastasis of HCC [14]. In line with these
findings, herewith, we used a murine model of melanoma
to investigate whether the timing of MSC administration
in melanoma-bearing mice was crucially important for
MSC-dependent modulation of antitumor immunity and
melanoma progression.
2. Material and Methods
2.1. Cells.MSCs isolated from bone marrow of C57BL/6 mice
were purchased fromGibco (Catalog number S1502-100). The
murine melanoma cell line B16F10, which is syngeneic to the
C57BL/6 background, was purchased from the American
Type Culture Collection (CRL-6475; ATCC, USA). Both types
of cells were cultured in complete Dulbecco’s modified Eagle
medium (DMEM) containing 10% heat-inactivated fetal
bovine serum (FBS), 100 IU/mL penicillin G, and 100μg/mL
streptomycin (Sigma-Aldrich, Munich, Germany), at 37°C in
a 5% CO2 incubator. MSCs in passage 4 and B16F10 cells in
passage 4 were used throughout the experiments.
2.2. Animals. Eight- to ten-week-old C57BL/6 mice were
used. Mice were maintained in animal breeding facilities of
the Faculty of Medical Sciences, University of Kragujevac,
Serbia. All procedures were performed in accordance with
the guidelines for the Principles of Laboratory Animal Care
and the Guide for the Care and Use of Laboratory Animals,
and all animals received humane care according to the cri-
teria outlined in the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health publication 86-23,
1985 revision). All experiments were approved by the Animal
Ethical Review Board of the Faculty of Medical Sciences,
University of Kragujevac, Serbia. Mice were housed in a
temperature-controlled environment with a 12-hour light-
dark cycle and were administered with standard laboratory
chow and water ad libitum. At least eight mice per group
were used in each experiment.
2.3. Melanoma Induction and Injection of MSCs. B16F10 cells
(5 × 105 cells, suspended in 200μL of phosphate-buffered
saline (PBS)) were subcutaneously injected in the left flank
of C57BL/6 mice. Immediately after, mice were divided into
four experimental groups. The first experimental group of
mice, 1 day after injection of B16F10 cells, intravenously
received MSCs (5 × 105 cells, suspended in 200μL of PBS;
B16F10+MSC1d-treated mice). The second experimental
group of B16F10-treated animals, 14 days after administra-
tion of B16F10 cells, intravenously received MSCs (5 × 105
cells, suspended in 200μL of PBS; B16F10+MSC14d-treated
mice). Mice from the third and fourth experimental groups
intravenously received 200μL of PBS at appropriate time
points (1 day (B16F10+PBS1d-treated mice) or 14 days after
B16F10 administration (B16F10+PBS14d-treated animals)).
All animals were sacrificed 28 days after the injection of
B16F10 cells.
2.4. Measurement of Tumor Growth and Progression. Once the
tumors were palpable, they were measured daily and tumor vol-
ume was calculated with the following formula: V = 4/3π ∗ a/2
∗ b/2 ∗ c/2 (a = length, b = width, and c = thickness) [15].
2.5. Measurement of Cytokines in Plasma Samples of Tumor-
Bearing Mice. Blood samples were collected from the facial
vein at days 1, 14, and 28 after the injection of B16F10 cells.
Mouse blood was kept in anticoagulant-containing tubes
and centrifuged for 10 minutes at 2000 g at 4°C. Supernatants
were stored at -20°C until needed. Concentration of tumor
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necrosis factor alpha (TNF-α), interferon gamma (IFN-γ),
transforming growth factor beta (TGF-β), and interleukin-
(IL-) 10 in mouse plasma samples were measured by using
enzyme-linked immunosorbent assay (ELISA) sets (R&D
Systems, Minneapolis, MN, USA), according to the manufac-
turer’s instructions [16].
2.6. Isolation of Tumor-Infiltrating Leucocytes. By using
forceps and scissors, subcutaneous tumors were resected en
bloc, including overlying and surrounding skin. After the
removal of surrounding skin, tumors were measured and
weighed. By using scissors, the tumors were minced, until all
large sections were processed into 1-2mm pieces which are
digested in 5mL of DMEM containing 1mg/mL collagenase
I, 1mMEDTA, and 2%FBS (all from Sigma-Aldrich,Munich,
Germany). After incubation of 2 hr at 37°C, the digested
tumor tissue was incubated with 4mL of trypsin and DNase
I (Roche Diagnostics), followed by passing through a 40μm
nylon filter. Single-cell suspensions were then processed for
flow cytometry analysis [17].
2.7. Flow Cytometry Analysis and Intracellular Staining of
Tumor-Infiltrating Leucocytes. Tumor-infiltrating leucocytes
were investigated for different cell surface and intracellular
markers with flow cytometry. Briefly, 1 × 106 cells were incu-
bated with anti-mouse F4/80, CD4, CD8, CD11c, NK1.1,
CD80, I-A, granzyme B, and Fas ligand (FasL) monoclonal
antibodies conjugated with fluorescein isothiocyanate
(FITC), phycoerythrin (PE), peridinin chlorophyll protein
(PerCP), or allophycocyanin (APC) (all from BDBiosciences,
San Jose, CA,USA) following themanufacturer’s instructions.
Immune cells derived from the tumors were concomitantly
stained for the intracellular content of TNF-α, IFN-γ, IL-12,
IL-4, and IL-17 by using the fixation/permeabilization kit
and anti-mouse monoclonal antibodies conjugated with
FITC, PE, PerCP, andAPC (BDBiosciences). For intracellular
cytokine staining, cells were stimulated with 50 ng/mL PMA
and 500ng/mL ionomycin for 5 h, and GolgiStop (BD Biosci-
ences) was added. Cells were fixed in Cytofix/Cytoperm,
permeated with 0.1% saponin, and stained with fluorescent
Abs. Flow cytometric analysis was conducted on a BD Biosci-
ences’ FACSCalibur and analyzed by using the Flowing Soft-
ware analysis program [17].
2.8. Statistical Analyses. The data were analyzed using statis-
tical package SPSS, version 21. The normality of distribution
was tested by the Kolmogorov-Smirnov test. The results were
analyzed using the Student t-test. All data in this study were
expressed as the mean ± standard error of themean ðSEMÞ.
Values of p < 0:05 were considered as statistically significant.
3. Results
3.1. MSC-Based Modulation of Melanoma Growth Depends on
the Time of MSC Administration. First, we examined whether
systemic application of MSCs affected melanoma growth. As
it is shown in Figure 1(a), tumors become palpable in B16F10
+MSC1d-treated mice 8 days later compared with other
experimental groups, suggesting that MSCs, intravenously
injected 24h after melanoma induction, prevented rapid tumor
growth. Starting from day 18, average tumor volumes were
significantly lower in B16F10+MSC1d-treated mice than in
B16F10+PBS1d-treated animals (p < 0:05; Figure 1(a)). Addi-
tionally, the average volume and weight of tumors removed
from B16F10+MSC1d-treated mice at day 28 were signifi-
cantly lower than melanomas taken from B16F10+PBS1d-
treated animals (Figures 1(b) and 1(c)), confirming that
MSCs, intravenously injected 24 h after melanoma induction,
efficiently suppressed tumor growth and progression.
Opposite to these data were results observed in
melanoma-bearing animals that intravenously received
MSCs 14 days after tumor induction (B16F10+MSC14d-
treated mice). Starting from day 18 (4 days after MSC injec-
tion), average tumor volumes were significantly greater in
B16F10+MSC14d-treated animals than in B16F10+PBS14d-
treated mice (p < 0:05; Figure 1(a)). Accordingly, at day 28,
average volume and weight of tumor removed from
B16F10+PBS14d-treated mice were significantly lower than
those of melanomas of B16F10+MSC14d-treated animals
(Figures 1(b) and 1(c)), confirming that MSCs administered
14 days after tumor induction remarkably enhanced mela-
noma growth and progression. In line with these findings,
the time of MSC injection was crucially important for their
effects on survival of melanoma-bearing mice. While the
lowest survival rate was observed in B16F10+MSC14d-
treated mice, all of the melanoma-bearing animals that
received MSCs 24 h after tumor induction survived till the
end of the experiment (Figure 1(d)).
Starting from day 14, MSCs transplanted 24 h after tumor
induction significantly reduced weight loss of melanoma-
bearing mice (p < 0:05; Figure 1(e)). Interestingly, weight
gain was also noticed in B16F10+MSC14d-treated animals
(p < 0:05; Figure 1(e)). While reduced weight of B16F10
+MSC1d-treated mice could be contributed to the MSC-
dependent suppression of tumor progression, weight gain,
noticed in B16F10+MSC14d-treated animals, may be a conse-
quence of significantly increased tumor weight which was
observed in these mice.
Since MSCs adopt proinflammatory (MSC1) or immu-
nosuppressive (MSC2) phenotype in response to the inflam-
matory and immunosuppressive cytokines to which they are
exposed [18], we analyzed and compared the concentration
of inflammatory (TNF-α, IFN-γ) and immunosuppressive
cytokines (IL-10, TGF-β) in plasma samples of melanoma-
bearing mice at the time of MSC administration. The ratios
of proinflammatory to anti-inflammatory cytokines (TNF-
α : IL-10, TNF-α : TGF-β, IFN-γ : IL-10, IFN-γ : TGF-β, IL-
12 : IL-10, and IL-12 : TGF-β) were significantly lower in
plasma samples of B16F10+PBS1d-treated mice compared
to B16F10+PBS14d-treated animals (p < 0:001; Figure 1(d)),
suggesting that MSCs, administered 1 day after the injection
of tumor cells, were exposed to the higher concentration of
immunosuppressive cytokines, while MSCs transplanted 14
days after tumor induction were exposed to the higher
concentration of inflammatory cytokines. Therefore, we
assume that, in response to the different concentration of
inflammatory and immunosuppressive cytokines to which
they were exposed, MSCs injected during the initial phase
of melanoma growth adopted proinflammatory (MSC1)
3Stem Cells International
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phenotype, while MSCs that were transplanted during the
progressive stage of melanoma development adopted immu-
nosuppressive (MSC2) phenotype.
3.2. MSCs, Injected 24 h after Melanoma Induction,
Significantly Enhanced NK and T Cell-Driven Antitumor
Immunity and Suppressed Tumor Growth and Progression.
Cellular makeup of tumors obtained from B16F10+PBS1d-
and B16F10+MSC1d-treated mice revealed that MSCs,
injected 24 h after melanoma induction, significantly
increased the total number of tumor-infiltrating cytotoxic
NK1.1+NK cells (p < 0:05; Figure 2(a)). The significantly
higher number of IFN-γ-producing (p < 0:05; Figure 2(b))
and FasL- and granzyme B-expressing (p < 0:05; Figures 2(c)
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Figure 1: MSC-based modulation of melanoma growth depends on the time of MSC administration. Delayed tumor growth, observed in
B16F10+MSC1d-treated mice, and rapid melanoma growth, noticed in B16F10+MSC14d-treated animals from day 18, were evidenced by
the measurement of tumor volumes at different days after tumor induction (a). Significantly lower average tumor volume (b) and tumor
weight (c) were observed in B16F10+MSC1d-treated mice than in B16F10+PBS1d-treated animals at day 28. Oppositely, average tumor
volume (b) and tumor weight (c) were significantly greater in B16F10+MSC14d-treated mice than in B16F10+PBS14d-treated animals at
day 28. The lowest survival rate was noticed in B16F10+MSC14d-treated animals, while all of B16F10+MSC1d-treated mice survived to the
last, 28th day of experiment (d). The difference in the survival between experimental groups was statistically nonsignificant (“ns”). Average
animal weight at different days after tumor induction demonstrates reduced weight loss in MSC-treated, melanoma-bearing mice (e). The
ratios of proinflammatory to anti-inflammatory cytokines (TNF-α : IL-10, TNF-α : TGF-β, IFN-γ : IL-10, IFN-γ : TGF-β, IL-12 : IL-10, and
IL-12 : TGF-β) were significantly lower in plasma samples of B16F10+PBS1d-treated mice than in plasma samples of B16F10+PBS14d-
treated animals (f). Plasma samples were collected 24 h and 14 days after tumor induction. Values are presented as the mean ± SEM; n = 8
mice/group. ∗p < 0:05, ∗∗∗p < 0:001.
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and 2(d)) NK cells in the tumors of B16F10+MSC1d-treated
mice indicated that MSCs, injected 24h after melanoma
induction, enhanced cytotoxic and antitumorigenic potential
of NK cells in tumor-bearing animals.
A significantly higher number of CD4+T helper (p < 0:05
; Figure 2(e)) and CD8+CTLs (p < 0:05; Figure 2(i)) were
present in the tumors of B16F10+MSC1d-treated mice than
in melanomas of B16F10+PBS1d-treated animals. Phenotype
and function of CD4+T helper and CD8+CTLs revealed that
MSCs, injected 24 h after melanoma induction, significantly
increased the presence of antitumorigenic and IFN-γ- and
TNF-α-producing CD4+Th1 cells (p < 0:05 for IFN-γ,
Figure 2(f); p < 0:001 for TNF-α, Figure 2(g)), IL-17-
producing CD4+Th17 cells (p < 0:001, Figure 2(h)), and
IFN-γ- and TNF-α-producing CD8+CTLs (p < 0:001,
Figures 2(j) and 2(k)) in melanoma-bearing animals.
In line with these findings, significantly higher plasma
levels of inflammatory and antitumorigenic cytokines TNF-
α (p < 0:05, Figure 2(l)) and IFN-γ (p < 0:05, Figure 2(m))
and significantly lower plasma levels of immunosuppressive
cytokines TGF-β (p < 0:05, Figure 2(n)) and IL-10 (p < 0:05,
Figure 2(o)) were observed in B16F10+MSC1d-treated mice,
indicating that MSCs, transplanted during the initial phase
of melanoma growth, enhanced antitumor immune response
in melanoma-bearing animals.
3.3. MSCs, Injected 14 Days after Melanoma Induction,
Promoted Tumor Growth by Suppressing Antigen-Presenting
Properties of Tumor-Infiltrating DCs and Macrophages and
by Reducing Tumoricidal Capacity of NK Cells and T
Lymphocytes. Compared to the tumors of B16F10+PBS14d-
treated mice, the significantly lower number of innate
immune cells that play an important role in antitumor immu-
nity (cytotoxic NK cells, inflammatory M1 macrophages and
DCs) was observed inmelanomas of B16F10+MSC14d-treated
animals. MSCs, transplanted 14 days after melanoma
induction, attenuated tumoricidal capacity of NK cells, as evi-
denced by the lower number of tumor-infiltrating granzyme
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Figure 2: MSCs, injected 24 h after melanoma induction, significantly enhanced NK and T cell-driven antitumor immunity and suppressed
tumor growth and progression. Significantly higher number of NK1.1+NK cells (a), IFN-γ-producing NK cells (b), FasL- and granzyme B-
expressing NK cells (c, d), CD4+T cells (e), IFN-γ- and TNF-α-producing CD4+Th1 cells (f, g), IL-17-producing CD4+Th17 cells (h),
CD8+CTLs (i), and IFN-γ- and TNF-α-producing CD8+CTLs (j, k) were noticed in the tumors of B16F10+MSC1d-treated mice compared
to the B16F10+PBS1d-treated animals. Significantly higher concentration of inflammatory and antitumorigenic cytokines TNF-α and IFN-
γ (l, m) and significantly lower concentration of immunosuppressive cytokines TGF-β and IL-10 (n, o) were noticed in plasma samples of
B16F10+MSC1d-treated mice compared to B16F10+PBS1d-treated animals. Values are presented as the mean ± SEM; n = 8 mice/group.
∗p < 0:05, ∗∗∗p < 0:001.
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B-expressing NK1.1+ cells in B16F10+MSCs14d-treated mice
(p < 0:05, Figure 3(a)). The significantly lower number of
tumor-infiltrating, I-A-expressing (p < 0:001, Figure 3(b)),
and IL-12-producing (p < 0:05, Figure 3(c)) F4/80+macro-
phages and CD80- and I-A-expressing CD11c+DCs
(p < 0:001, Figures 3(d) and 3(e)) indicated that MSCs allevi-
ated capacity of antigen-presenting cells for optimal activa-
tion of T cell-driven antitumor immune response.
As it is shown in Figure 4, MSCs, injected 14 days after
melanoma induction, suppressed tumoricidal capacity of
CD8+CTLs, CD4+Th1, and Th17 lymphocytes. Both sub-
populations of effector T lymphocytes, CD4+T helper cells
(p < 0:001, Figure 4(a)) and CD8+CTLs (p < 0:001,
Figure 4(d)), were significantly reduced in the melanomas
of B16F10+MSC14d-treated mice compared to B16F10
+PBS14d-treated animals. Intracellular staining revealed that
MSCs suppressed production of tumoricidal cytokines
(IFN-γ and IL-17) in CD4+Th1 and Th17 cells (p < 0:05
for TNF-α and IL-17, Figures 4(b) and 4(c)) and in CTLs
(p < 0:05 for IFN-γ and IL-17, Figures 4(e) and 4(f)) of
B16F10+MSC14d-treated mice, preventing generation of
optimal TNF-α, IFN-γ, and IL-17-driven antitumor immune
response. Additionally, a significantly lower number of gran-
zyme B-expressing CD8+CTLs were observed in the tumors
of B16F10+MSC14d-treated mice (p < 0:05, Figure 4(g)), indi-
cating that MSCs injected 14 days after tumor induction sig-
nificantly reduced the presence of cytotoxic and proapoptotic
CD8+CTLs in the tumors of melanoma-bearing animals.
Furthermore, significantly lower levels of antitumori-
genic cytokines TNF-α and IFN-γ (p < 0:05, Figures 4(h)
and 4(i)) and significantly higher levels of TGF-β and
IL-10 (p < 0:001, Figures 2(j) and 2(k)) were noticed in
the plasma samples of B16F10+MSC14d-treated mice, indi-
cating that MSCs, injected during the progressive stage of
melanoma development, attenuated antitumor immunity
by increasing production of immunosuppressive cytokines
in tumor-bearing animals.
4. Discussion
It is well known that exogenously administered MSCs could
migrate to the tumor site where it regulates tumor growth
and progression by modulating antitumor immune response
[19]. Opposite findings, demonstrating a pro- or anticancer
action of transplanted MSCs, were reported in different
experimental studies [9–11]. While several research groups
revealed that MSCs increased tumor progression [9–11];
results presented in other animal studies showed that
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Figure 4: Continued.
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transplantation of MSCs led to the alleviation of tumor
growth [12–14]. Herewith, we demonstrated that MSCs exert
opposite, anti- or protumorigenic action, in the different
stages of melanoma progression. MSCs injected in the initial
phase of melanoma growth showed a tumor-suppressive
effect, while MSCs, administered in the progressive stage of
melanoma development, significantly enhanced tumor
growth and expansion (Figure 1). In line with our findings
are results obtained by Zong and colleagues which are show-
ing that MSC-based effects on progression and metastasis of
HCC depend on the stage of cancer development [14].
Although MSCs exhibit tumor-inhibitory effects in the initial
phase of HCC development, potent suppression of antitumor
immunity accompanied by enhanced HCC progression and
metastasis is observed in HCC-bearing rats that received
MSCs in the progressive stage of tumor growth [14]. MSCs
injected in the initial stage of HCC progression engraft in
the microenvironment with the reduced expression of proin-
flammatory cytokines, while MSCs injected in the progres-
sive phase of HCC growth are exposed to the high levels of
inflammatory cytokines [14]. According to the conclusion
of Zong and coworkers, the interactions between transplanted
MSCs and tumormicroenvironment and diverse outcomes of
MSC-based therapy depend on the strength of local and
systemic inflammatory response during the different phases
of hepatocarcinogenesis [14].
Several lines of evidence demonstrated that the ratio
between inflammatory and anti-inflammatory cytokines in
the microenvironment to which MSCs are exposed directly
affects their phenotype and function [18, 20, 21].WhenMSCs
engraft in the tissue with low levels of inflammatory cytokines
and high levels of immunosuppressive cytokines, they adopt
proinflammatory (MSC1) phenotype, becoming capable of
eliciting potent inflammatory response [20]. On the contrary,
MSCs exposed to the high concentration of inflammatory
cytokines develop immunosuppressive (MSC2) phenotype,
produce a large number of anti-inflammatory factors, and
inhibit immune response [18, 20, 21].
Dynamic balance of pro- and anti-inflammatory cyto-
kines within tumor microenvironment regulates melanoma
growth and progression [22]. Melanoma cell-derived immu-
nosuppressive cytokines TGF-β and IL-10 play a crucially
important role in the process of tumor initiation [23–25].
Tumor cell-derived TGF-β acts on CTLs to specifically
repress the expression of perforin, granzyme B, and FasL
and to reduce the production of IFN-γ, resulting in a signif-
icant attenuation of CTL-mediated tumor cytotoxicity [26].
Through the production of IL-10, melanoma cells prevent
maturation of DCs, suppress production of Th1-inducing
cytokine IL-12 in DCs, and inhibit their antigen-presenting
properties, attenuating generation of effector CD4+Th1 and
CD8+CTLs [27]. Furthermore, melanoma cell-primed DCs
produce large amounts of immunosuppressive cytokines
and significantly contribute to the development of immuno-
suppressive microenvironment that favors enhanced tumor
growth and progression [23–25]. Excessive proliferation of
melanoma cells activates stromal and melanoma-residing
immune cells (macrophages, DCs, NK, and NKT cells) which
produce a large amount of proinflammatory chemokines and
cytokines (TNF-α, IL-12, IFN-γ, and IL-17) that facilitate the
massive influx of circulating leucocytes in the tumors and
enable generation and expansion of tumorotoxic CD8+CTLs,
CD4+Th1, and Th17 cells in the peripheral lymph organs
[28]. Generation of potent antitumor immune response
during the progressive phase of melanoma growth results in
the development of local and systemic inflammation that
attenuates melanoma progression [22]. In line with these
findings, we assume that changes in the balance between
pro- and anti-inflammatory cytokines at the time of MSC
administration (initial versus progressive stage of melanoma
growth) were crucially responsible for the generation of
inflammatory (MSC1) or immunosuppressive (MSC2) phe-
notype in MSCs after their engraftment in the melanoma-
bearing mice (Figure 1).
MSC1, generated in the immunosuppressive microenvi-
ronment, produce lymphocyte-attracting chemokines (CCL5,
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Figure 4: MSCs, injected 14 days after melanoma induction, increased plasma levels of immunosuppressive cytokines and suppressed T cell-
driven antitumor immune response in melanoma-bearing animals. Significantly lower number of tumor-infiltrating CD4+T cells (a), TNF-α
and IL-17-producing CD4+Th1 and Th17 cells (b, c), CD8+CTLs (d), IFN-γ and IL-17-producing CD8+CTLs (e, f), granzyme B-expressing
CD8+CTLs (g), significantly lower plasma levels of antitumorigenic cytokines TNF-α and IFN-γ (h, i), and significantly higher plasma levels
of immunosuppressive cytokines TGF-β and IL-10 (j, k) were noticed in B16F10+MSC14d-treated mice compared to the B16F10+PBS14d-
treated animals. Values are presented as the mean ± SEM; n = 8 mice/group. ∗p < 0:05, ∗∗∗p < 0:001.
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CXCL9, and CXCL10) that recruit CTLs and NK cells to the
sites of injury and inflammation [20]. Additionally, MSC1
enhance NK and T cell-dependent antitumor immune
response by increasing production of proinflammatory cyto-
kines (TNF-α, IFN-γ, and IL-17) in these cytotoxic cells [18].
NK cells and CTLs, in a FasL, perforin, and granzyme B-
dependent manner, induce apoptosis of melanoma cells [29,
30], while, in an IFN-γ and IL-17-dependent manner, enhance
antigen-presenting properties of DCs and proinflammatory
properties of tumor-infiltrating neutrophils, contributing to
the generation of the strong antitumor immune response
[31, 32]. In line with these findings, we assume that MSC
transplanted in the immunosuppressive microenvironment
of B16F10+MSC1d-treated animals acquired MSC1 pheno-
type. MSC1 cells inhibited production of immunosuppres-
sive cytokines (IL-10 and TGF-β) in tumor-infiltrating
immune cells and promoted generation and influx of cyto-
toxic, FasL, perforin, and granzyme B-expressing and IFN-
γ- and IL-17-producing CTLs and NK cells in the tumors
of B16F10+MSC1d-treated mice which resulted in reduced
melanoma growth and progression (Figure 2).
In contrast to the B16F10+MSC1d-treated animals, MSCs
that were transplanted in B16F10+MSC14d-treated mice were
exposed to the higher levels of inflammatory cytokines
(Figure 1) and generated immunosuppressive, MSC2 pheno-
type. MSC2, in an IL-10 and TGF-β-dependent manner,
inhibit maturation of DCs and reduce production of inflam-
matory cytokines and expression of costimulatory and major
histocompatibility class (MHC) II molecules on DCs and
macrophages, attenuating their antigen-presenting proper-
ties [33]. In line with these findings, we observed a signifi-
cantly lower number of CD80 and I-A-expressing DCs and
reduced presence of IL-12-producing and I-A-expressing
macrophages in the tumors of B16F10+MSC14d-treated mice
compared to B16F10+PBS14d-treated animals (Figure 3).
MSC2-mediated alleviation of antigen-presenting capacity
of tumor-infiltrating DCs resulted in unoptimal activation
of naïve CD4+ and CD8+T lymphocytes which led to the
reduced presence of effector CD4+Th1 and Th17 cells and
CD8+CTLs in the tumors of B16F10+MSC14d-treated mice
(Figure 4). The reduced number of tumor-infiltrating CTLs,
Th1, and Th17 cells corresponded to the increased plasma
levels of TGF-β and IL-10 in B16F10+MSC14d-treated ani-
mals, indicating the important role of TGF-β and IL-10 in
MSC-mediated suppression of T cell-driven antitumor
immune response. It is well known that MSC2, through the
production of TGF-β and IL-10, directly suppress activation
of the Jak-Stat signaling pathway in proliferating T lympho-
cytes, causing the G1 cell cycle arrest [34]. Additionally,
MSC2-sourced TGF-β and IL-10 downregulate production
of inflammatory cytokines and reduce cytotoxicity of Th1
and Th17 cells and CTLs, contributing to the enhanced
tumor growth and progression [35, 36]. Therefore, we believe
that MSCs that were injected in B16F10-treated mice during
the progressive stage of melanoma growth adopted immuno-
suppressive MSC2 phenotype and in a TGF-β and IL-10-
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Figure 5: The effects of MSCs on antimelanoma immunity depend on the timing of their administration. MSCs transplanted during the
initial phase of melanoma growth exerted tumor-suppressive effects. Since these MSCs were exposed to the immunosuppressive
microenvironment (established by IL-10 and TGF-β-producing tumor cells), they acquired inflammatory, MSC1 phenotype and induced
expansion of cytotoxic NK cells and antitumorigenic CD8+CTLs, CD4+Th1, and Th17 lymphocytes, resulting in attenuated melanoma
growth and progression. On the contrary, MSCs transplanted during the progressive stage of melanoma development were exposed to the
high concentration of inflammatory cytokines (TNF-α and IFN-γ) and generated immunosuppressive, MSC2 phenotype. Accordingly,
enhanced melanoma growth and reduced number of tumor-infiltrating antigen-presenting cells (macrophages and DCs), cytotoxic CTLs
and NK cells, and antitumorigenic CD4+Th1 and Th17 lymphocytes were observed in melanoma-bearing mice which received MSCs
during the progressive stage of tumor development.
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dependent manner attenuated antitumor immune response,
resulting in increased melanoma growth.
In summing up, MSCs have an opposite role in the
different stages of melanoma progression. MSCs trans-
planted during the initial phase of melanoma growth exert
tumor-suppressive effect, whileMSCs injected in the progres-
sive stage of melanoma development suppressed antitumor
immunity and enhanced tumor expansion (Figure 5). There-
fore, the timing ofMSC administration into the tumormicro-
environment is crucially important for MSC-dependent
modulation of melanoma progression.
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